BRIEF published on 07/02/2025 at 15:23, 1 year 2 months ago Divulgation du groupe Vanguard sur Direct Line Insurance Group Actionnariat Groupe Vanguard Code De Prise De Contrôle Divulgation Assurance Direct Line
BRIEF published on 07/02/2025 at 15:23, 1 year 2 months ago The Vanguard Group's Disclosure on Direct Line Insurance Group Disclosure Takeover Code Vanguard Group Shareholding Direct Line Insurance
PRESS RELEASE published on 07/02/2025 at 15:18, 1 year 2 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 4.52% interest in Direct Line Insurance Group plc. They made purchases and sales of 10 10/11p ordinary securities The Vanguard Group Ownership Disclosure Financial Disclosure Stock Transactions Direct Line Insurance Group Plc
BRIEF published on 07/01/2025 at 15:37, 1 year 2 months ago Vanguard Group Discloses Position in Direct Line Insurance Takeover Code Vanguard Group Direct Line Insurance Public Position Disclosure Aviva Plc
BRIEF published on 07/01/2025 at 15:37, 1 year 2 months ago Le groupe Vanguard dévoile sa position dans Direct Line Insurance Groupe Vanguard Code De Prise De Contrôle Aviva Plc Assurance Direct Line Divulgation De Position Publique
PRESS RELEASE published on 07/01/2025 at 15:32, 1 year 2 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.48% ownership in Direct Line Insurance Group plc on 30 June 2025. Additional disclosure for Aviva plc made The Vanguard Group Ownership Disclosure Financial Disclosure Direct Line Insurance Group Plc Aviva Plc
BRIEF published on 06/27/2025 at 15:10, 1 year 2 months ago The Vanguard Group Discloses Significant Stake in Direct Line Insurance Group Form 8.3 Takeover Code Vanguard Group Stake Disclosure Direct Line Insurance
BRIEF published on 06/27/2025 at 15:10, 1 year 2 months ago Le groupe Vanguard révèle une participation significative dans Direct Line Insurance Group Groupe Vanguard Code De Prise De Contrôle Formulaire 8.3 Divulgation Des Enjeux Assurance Direct Line
PRESS RELEASE published on 06/27/2025 at 15:05, 1 year 2 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.48% stake in Direct Line Insurance Group plc as of 26 June 2025 under Rule 8.3 of the Takeover Code Takeover Code Vanguard Group Financial Disclosure Stake Disclosure Direct Line Insurance Group
BRIEF published on 06/26/2025 at 16:15, 1 year 2 months ago Le groupe Vanguard révèle sa position dans Direct Line Insurance Règle 8.3 Code De Prise De Contrôle Le Groupe Vanguard Divulgation Des Stocks Assurance Direct Line
Published on 09/11/2026 at 04:00, 5 hours 11 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 10 hours 46 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 17 hours 51 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 18 hours 11 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 09:05, 6 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 11 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 11 minutes ago Mountain Alliance AG invests in Evolved Aerospace and expands its involvement in the European defence technology market
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 hours 11 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 13 hours 41 minutes ago Availability of the 2026 Interim Financial Report
